Vertex Pharmaceuticals VRTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.5B+17.5% | $5.09B+11.3% | $4.95B-5.7% | $4.98B+8.5% | $4.69B-48.9% | ||
| $1.75B+14.9% | $1.52B-1.5% | $1.35B+4.8% | $1.41B+16.1% | $1.53B+50.6% | ||
| $2B+10.6% | $2.05B+27.6% | $1.95B+11.2% | $1.89B+14.3% | $1.81B+0.7% | ||
| $1.77B+29.9% | $1.69B+39.9% | $1.63B+50.7% | $1.5B+63.9% | $1.36B+67.2% | ||
| $11.73B+17.2% | $11.2B+16.7% | $10.57B+7.8% | $10.43B+16.6% | $10.01B-24.7% | ||
| $1.09B0.0% | $1.09B0.0% | $1.09B0.0% | $1.09B0.0% | $1.09B0.0% | ||
| $26.48B+15.8% | $25.64B+13.8% | $24.86B+11.8% | $24.04B+19.4% | $22.88B-4.3% | ||
| $489.3M+10.0% | $461.7M+11.8% | $420.3M+6.2% | $442.3M+34.9% | $445M+26.6% | ||
| $3.88B+2.6% | $3.86B+8.3% | $4.48B+12.6% | $4.14B+16.7% | $3.78B-0.3% | ||
| $7.12B+11.6% | $6.98B+13.9% | $7.54B+14.1% | $6.86B+28.1% | $6.38B+18.9% | ||
| $14.59B+42.3% | $13.56B+41.2% | $12.37B+42.3% | $11.29B+47.6% | $10.25B-8.8% | ||
| $19.36B+17.4% | $18.67B+13.7% | $17.32B+10.8% | $17.18B+16.2% | $16.5B-11.1% | ||
| $26.48B+15.8% | $25.64B+13.8% | $24.86B+11.8% | $24.04B+19.4% | $22.88B-4.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's total assets?
- Vertex Pharmaceuticals (VRTX) holds $26.5B in total assets, up 15.8% year over year.
- How much debt does Vertex Pharmaceuticals have?
- Vertex Pharmaceuticals carries $2.0B in total debt against $19.4B of shareholders' equity, a debt-to-equity ratio of 0.10.
- How much cash does Vertex Pharmaceuticals have?
- Vertex Pharmaceuticals holds $5.5B in cash and equivalents.
- Can Vertex Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.02 — current assets exceed current liabilities.
- Where does Vertex Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
